FilingReader Intelligence
SSY Group wins China drug approvals
July 18, 2025 at 04:09 AM UTC•By FilingReader AI
SSY Group received NMPA approval for two drugs in China: Ketotifen Fumarate Eye Drops for seasonal allergic conjunctivitis and Calcium Gluconate Injection for acute hypocalcemia and poisoning treatment.
The eye drops mark the company's third ophthalmic medicine, strengthening its product portfolio.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
HKEX:2005•Hong Kong Exchange
News Alerts
Get instant email alerts when SSY Group publishes news
Free account required • Unsubscribe anytime